Enveric Biosciences Announces Development Of Phase 1-Ready Formulation For EB-373 And Initiation Of Scaled Up Manufacturing
Portfolio Pulse from Happy Mohamed
Enveric Biosciences has developed a Phase 1-ready formulation for EB-373, a psilocin prodrug for anxiety disorder treatment, and initiated scaled-up manufacturing. The new formulation is expected to enhance scalability, stability, and delivery for ongoing preclinical studies and planned clinical development.
June 26, 2023 | 12:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Enveric Biosciences' development of a Phase 1-ready formulation for EB-373 and initiation of scaled-up manufacturing may positively impact the company's stock price.
The development of a Phase 1-ready formulation for EB-373 and the initiation of scaled-up manufacturing indicate progress in Enveric Biosciences' product pipeline. This may lead to increased investor confidence and a positive impact on the company's stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100